Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

We conducted a retrospective cohort study to assess whether treatment with
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …

Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …

Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …

Long Covid–the disease encompassing the post-acute sequelae of SARS-CoV-2 (PASC)—
affects millions of people around the world. Prevention of PASC is an urgent public health …

Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods …

Background There is an urgent need for therapeutic strategies for inpatients with severe or
critical COVID-19. The evaluation of the clinical benefits of nirmatrelvir and ritonavir (Nmr/r) …